Zydus Lifesciences share news, announcements and annual reports
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Zydus Lifesciences Limited · Formerly Cadila Healthcare · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2000
Last close ₹1,245.50up ₹61.10 (5.16%)BSE ₹1,244.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,184.40.
30 Oct: open ₹1,190.00, high ₹1,248.90, low ₹1,182.00
52-week range of traded prices to 30 Oct 2026
₹835.50Low, 2 Apr 2026₹1,248.90High, 30 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,24,239 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.53
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 24.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 36,60,70935.2% delivered
Zydus Lifesciences board meetings
113 filed, newest first. Page 3 of 3.
Jan 2009
12 Jan · Board meeting
To consider amongst others unaudited financial results for the quarter ended on December 31, 2008.
Oct 2008
10 Oct · Board meeting
To consider amongst others unaudited financial results for the quarter/half year ended on September 30, 2008.
Jul 2008
18 Jul · Board meeting
To consider amongst other unaudited financial results for the quarter ended on June 30, 2008.1 Jul · Board meeting
To approve the "Composite Scheme of Arrangement between Cadila, Carnation and Zydus Hospitals and Medical Research Private Limited" to effect restructuring of the Consumer Products Division of Cadila and Carnation and also to realign the holding structure of the Company into Carnation based on the recommendations of consultants and to approve share swap ratios, under the Scheme, after considering the reports of the valuers.
Jun 2008
17 Jun · Board meeting
Outcome of the Meeting of Board of Directors of the Company held on June 17, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Jun · Board meeting
To consider options to consolidate / restructure the Consumer Product business of the group, including its listed subsidiary, namely Carnation Nutra-Analogue Foods Limited.
Apr 2008
15 Apr · Board meeting
To consider the audited Annual Accounts of the Company for the year ended March 31, 2008 and the Board will consider interalia with other agenda items recommendation of dividend on Equity Shares for the year, 2007 - 08.
Jan 2008
14 Jan · Board meeting
To consider apart from other agenda items unaudited financial results for the quarter ended on December 31, 2007.
Oct 2007
11 Oct · Board meeting
Meeting on 26 Oct 2007: “Unaudited Financial Results for the Qtr ended Sept 30, 2007”
Jul 2007
11 Jul · Board meeting
Meeting on 31 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
Jun 2007
13 Jun · Board meeting
To consider amongst other agenda items to issue Foreign Currency Convertible Bonds (FCCBs) / ADRs / GDRs, etc. subject to approval of shareholders and such other statutory authorities.
Apr 2007
17 Apr · Board meeting
To consider the audited Annual Accounts of the Company for the year ended March 31, 2007 and the Board will consider interalia with other agenda items recommendation of dividend on Equity Shares for the year, 2006 - 07.
Jan 2007
5 Jan · Board meeting
To consider apart from other agenda items unaudited financial results for the quarter ended on 31st December, 2006.